HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Bowenoid papulosis — Clinical Guidelines

Overview

Malignant atrophic papulosis, also known as Degos' disease, is a rare systemic vasculopathy characterized by characteristic skin lesions and frequently involving the gastrointestinal tract and central nervous system 1 5.

Diagnosis

Clinical Presentation: Characteristic skin lesions (papules) often accompanied by gastrointestinal and neurological symptoms 1 4.

Histopathology: Biopsy showing necrobiosis with cone-shaped zones of necrosis, thrombosis in small vessels, and minimal inflammatory reaction 5 6.

Imaging and Tests: Neuroimaging may reveal infarcts; coagulation studies can identify coagulopathy 4.

Genetic Consideration: Family history suggestive of potential genetic predisposition 3.

Management

First-Line Treatments: No definitive first-line treatment established; systemic immunosuppressants have shown limited efficacy 2 5.

Adjunctive Therapies: Heparin occasionally reported to be beneficial 5.

Supportive Care: Focus on managing complications such as gastrointestinal bleeding and neurological deficits 4.

Special Populations

Pediatrics: Severe visual and neurological impairment can occur in pediatric cases 1.

Comorbidities: Coagulopathy often coexists with severe neurological involvement 4.

Key Recommendations

Biopsy Confirmation: Essential for definitive diagnosis due to characteristic histopathological features (Evidence: Strong 5 6).

Monitor for Complications: Regular assessment for gastrointestinal and neurological involvement is crucial (Evidence: Moderate 1 4).

Consider Genetic Counseling: Given potential familial clustering, genetic counseling may be warranted for affected families (Evidence: Expert opinion 3).

Use Heparin with Caution: May be considered for its potential benefits in managing thrombotic aspects, though evidence is limited (Evidence: Weak 5).

References

1 Gutiérrez-Pascual M, Hernández-Martín A, Colmenero I, García-Peñas JJ, López-Pino MA, Torrelo A. Malignant atrophic papulosis: a case report with severe visual and neurological impairment. Pediatric dermatology 2011. link 2 Tribble K, Archer ME, Jorizzo JL, Sanchez R, Solomon AR, Gardner FH et al.. Malignant atrophic papulosis: absence of circulating immune complexes or vasculitis. Journal of the American Academy of Dermatology 1986. link70180-1) 3 Kisch LS, Bruynzeel DP. Six cases of malignant atrophic papulosis (Degos' disease) occurring in one family. The British journal of dermatology 1984. link 4 Dastur DK, Singhal BS, Shroff HJ. CNS involvement in malignant atrophic papulosis (Kohlmeier-Degos disease): vasculopathy and coagulopathy. Journal of neurology, neurosurgery, and psychiatry 1981. link 5 Degos R. Malignant atrophic papulosis. The British journal of dermatology 1979. link 6 Muller SA, Landry M. Malignant atrophic papulosis (Degros disease). A report of two cases with clinical and histological studies. Archives of dermatology 1976. link

Bowenoid papulosis